【摘要】

【摘要】目的：探究丁苯酞联合银杏叶胶囊治疗帕金森症伴抑郁、睡眠障碍患者的临床疗效。
方法：研究对象选取为2016.3~2017.8之间我院收治的118例帕金森症伴抑郁、睡眠障碍患者，采用数字表法随机分为观察组及对照组各59例，对照组单纯采用银杏叶胶囊治疗，观察组则在对照组基础上加用丁苯酞治疗，分别采用帕金森病综合评分（UPDRS）II、UPDRS III、汉密尔顿抑郁量表（HAMD）、帕金森病睡眠量表（PDSS）评价两组患者治疗前后的疗效情况。
结果：治疗前、治疗4周时两组患者UPDRS II、III评分对比无显著差异（P＞0.05），治疗8周时观察组显著低于对照组（P＜0.05）；治疗前两组患者HAMD评分对比无显著差异（P＞0.05），治疗4周、治疗8周时观察组显著低于对照组（P＜0.05）；治疗前两组患者PDSS评分对比无显著差异（P＞0.05），治疗4周、治疗8周时观察组显著高于对照组（P＜0.05）。
结论：丁苯酞联合银杏叶胶囊治疗帕金森症伴抑郁、睡眠障碍患者的疗效确切，能够有效改善患者的临床症状，值得在临床上推广和应用。

【Abstract】

[Abstract] Objective: To explore the clinical efficacy of butylphthalide combined with Ginkgo biloba extract in the treatment of Parkinson's disease with depression and sleep disorders. METHODS: A total of 118 patients with Parkinson's disease with depression and sleep disorders were randomly divided into observation group and control group (n = 59). The control group was treated with Ginkgo biloba capsule (UPDRS) II, UPDRS III, Hamilton Depression Scale (HAMD), Parkinson's Disease Sleep Scale (PDSS) were evaluated on the basis of the control group and the control group The efficacy of the two groups before and after treatment.
Results: There was no significant difference in UPDRS II and III scores between the two groups before and after treatment (P> 0.05). At the 8th week of treatment, the observation group was significantly lower than the control group (P <0.05). Before treatment, HAMD (P> 0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05). There was no significant difference between the two groups (P> 0.05) 4 weeks, 8 weeks after treatment, the observation group was significantly higher than the control group (P <0.05).
Conclusion  : Butylphthalide combined with Ginkgo biloba capsule in the treatment of Parkinson's disease with depression, sleep disorders in patients with exact effect, can effectively improve the clinical symptoms of patients, it is worth to promote and apply in clinical practice.